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2Abstract:
Duchenne muscular dystrophy is a fatal muscle wasting disorder. Lack of dystrophin 
compromises the integrity of the sarcolemma and results in myofibres that are highly 
prone to contraction induced injury. rAAV mediated dystrophin gene transfer strategies
to muscle for the treatment of DMD have been limited by the small cloning capacity of 
rAAV vectors and high titres needed to achieve efficient systemic gene transfer. Here 
we assess the impact of codon optimisation on microdystrophin (∆AB/R3-R18/∆CT) 
expression and function in the mdx mouse and compare the function of two different 
configurations of codon-optimised microdystrophin genes (∆AB/R3-R18/∆CT & ∆R4-
R23/∆CT), under the control of a muscle restrictive promoter (Spc5-12). Codon 
optimisation of microdystrophin significantly increases levels of microdystrophin mRNA 
and protein following intramuscular and systemic administration of plasmid DNA or 
rAAV2/8. Physiological assessment demonstrates that codon optimisation of ∆AB/R3-
R18/∆CT results in significant improvement in specific force, but does not improve 
resistance to eccentric contractions compared to non-codon-optimised ∆AB/R3-
R18/∆CT. However, codon-optimised microdystrophin ∆R4-R23/∆CT completely 
restored specific force generation and provided substantial protection from contraction 
induced injury. These results demonstrate that codon optimisation of microdystrophin
under the control of a muscle specific promoter can significantly improve expression 
levels such that reduced titres of rAAV vectors will be required for efficient systemic 
administration. 
1Introduction:
Duchenne muscular dystrophy (DMD) is a severe muscle wasting disorder caused by a 
lack of dystrophin protein in skeletal muscle. Loss of dystrophin compromises the 
integrity of the muscle cell membrane and results in muscle fibres that are highly prone 
to contraction induced injury. Consequently there are progressive rounds of 
degeneration and regeneration of the muscle leading to the replacement of muscle 
fibres with non-contractile fibrotic tissue and fatty infiltrates. Recent reports have 
suggested that a minimum of 30% of normal dystrophin levels need to be present 
uniformly in all myofibres to prevent muscular dystrophy in humans, which is supported 
by data from transgenic mdx mice (1, 2). Efficient systemic gene transfer of dystrophin is 
crucial if restoration of muscle function is to be achieved. 
Recombinant adeno-associated viral (rAAV) vectors are being investigated intensively 
for their potential to restore dystrophin expression in dystrophic muscle and thereby
improve muscle function and stabilise or halt disease progression (3-7). Two main 
hurdles exist in the use of rAAV vectors for DMD gene therapy; the packaging capacity 
of rAAV vectors and the very high titres of rAAV that have been required to achieve 
efficient systemic administration (6, 7). To overcome the first issue, ‘microgenes’ 
encoding for truncated microdystrophin proteins have been engineered and tested 
rigorously in dystrophic mouse muscle (4, 8, 9). A number of these microdystrophin 
proteins have been demonstrated to improve, but not completely normalise, a range of 
markers of the dystrophic phenotype. Restoration of the dystrophin associated protein 
complex (DAPC), stabilisation of muscle degeneration and improvements in muscle 
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2function have been demonstrated following delivery of microdystrophin at different
stages of disease progression (6, 10, 11). However, microdystrophin proteins are less 
able to protect dystrophic muscle from contraction induced injury (7, 8, 10).   
Secondly, although much progress has been made in the systemic delivery of rAAV 
microdystrophin vectors, this success has been achieved with the use of constitutive 
viral promoters driving gene expression and the injection of very high titres of rAAV.  
Although such systems are invaluable in a research setting, it will be necessary to 
develop rAAV vectors that can achieve efficient gene transfer and expression at lower 
viral titres with a muscle restrictive promoter driving microdystrophin expression that will 
be more applicable for use in a clinical setting.
In this study, we tested the hypothesis that the optimisation of codon usage within the 
microdystrophin gene would result in increased levels of transgene expression such that 
the viral dose needed for effective reconstitution of dystrophin could be reduced. In 
contrast to treatment with non-codon-optimised rAAV2/8 microdystrophin, mdx mice 
treated with codon-optimised rAAV2/8 microdystrophin showed increased numbers of 
dystrophin positive fibres, improved muscle function and amelioration of dystrophic 
pathology. In addition, we demonstrate that systemic administration of codon-optimised 
rAAV2/8 microdystrophin under the control of a muscle restrictive promoter can result in 
skeletal muscle expression at doses of 3x1011vg/mouse (1x1013vg/kg).
3Results:
Codon optimisation of microdystrophin increases mRNA and protein levels 
following plasmid gene transfer.
To assess the impact of codon optimisation on microdystrophin expression, plasmids 
expressing either non codon-optimised human ∆AB/R3-R18/∆CT, codon-optimised
human ∆AB/R3-R18/∆CT or codon-optimised human ∆R4-R23/∆CT were transfected 
into HEK293T cells and total RNA was collected 48 hours post transfection. Quantitative 
RT-PCR demonstrates that microdystrophin mRNA levels are increased up to 30-fold
(p<0.05) following transfection with codon-optimised constructs compared to the control
plasmid (Figure 1a). These plasmids were also tested in vivo by electrotransfer into the 
muscle of 6-8 week old mdx mice. Histological analysis of the tibialis anterior (TA)
muscles at 7 days post injection demonstrates that treatment with a codon-optimised
microdystrophin plasmid significantly increases the number of dystrophin positive fibres 
compared to a non codon-optimised microdystrophin (p<0.05). No difference is 
observed between codon-optimised ∆AB/R3-R18/∆CT and ∆R4-R23/∆CT when 
comparing levels of mRNA and dystrophin positive fibres (Figure 1a-b). Electrotransfer 
with codon-optimised ∆AB/R3-R18/∆CT and ∆R4-R23/∆CT achieves robust staining of 
microdystrophin at the sarcolemma, although cytoplasmic staining of microdystrophin 
was observed with ∆R4-R23/∆CT but not with ∆AB/R3-R18/∆CT (Figure 1c-d).
Codon optimisation of microdystrophin leads to efficient systemic gene transfer
at low titres of rAAV2/8.
4The impact of codon optimisation on rAAV based gene therapy was assessed, as 
despite the development of novel serotypes of rAAV, very high titres of rAAV are 
currently required to achieve efficient systemic gene transfer to the skeletal muscle (7, 
12). 3x1011vg of rAAV2/8 expressing either ∆AB/R3-R18/∆CT or codon-optimised
∆AB/R3-R18/∆CT and ∆R4-R23/∆CT was delivered via the tail vein of young adult mdx 
mice (10 weeks old). Cardiac and skeletal muscles were recovered at 12 weeks post 
treatment and assessed histologically.
Following systemic administration of rAAV2/8 ∆AB/R3-R18/∆CT vectors, codon 
optimisation was observed to have a significant impact on the number of dystrophin 
positive cardiomyocytes detected in cardiac muscle (p<0.001). However, treatment with 
codon-optimised ∆R4-R23/∆CT resulted in levels of dystrophin expression in the cardiac 
tissue at significantly higher levels than achieved with treatment of any other 
microdystrophin (p<0.001) (Figure 2). Further assessment demonstrates that 
administration of rAAV2/8 vectors expressing ∆AB/R3-R18/∆CT does not result in 
notable levels of dystrophin expression with any of the skeletal muscles analysed and 
that codon optimisation has no impact on this. However, systemic administration of 
rAAV2/8 vectors expressing codon-optimised ∆R4-R23/∆CT results in marked 
dystrophin expression in the skeletal muscle, most notably in the gastrocnemius muscle 
group, with expression also observed within the diaphragm (Figure 3). 
Codon optimisation of microdystrophin leads to greater improvements in mdx 
muscle pathology. 
5Intramuscular injection of neonatal mdx mice with 7.5x109 vg of rAAV2/8 expressing 
either codon-optimised human ∆AB/R3-R18/∆CT, ∆R4-R23/∆CT or non-codon-
optimised ∆AB/R3-R18/∆CT under the control of the muscle specific promoter Spc5-12, 
results in sustained expression of microdystrophin for at least 8 weeks (end of 
experiment), with no evidence of an immune response to the human transgene. 
Microdystrophin is correctly localised to the sarcolemma and as has previously been 
demonstrated restores localisation of the DAPC. As was observed following 
electrotransfer much greater numbers of dystrophin positive fibres can be achieved 
following treatment with a codon-optimised construct compared to a control 
microdystrophin construct (∆AB/R3-R18/∆CT). However, unlike following electrotransfer, 
the number of dystrophin positive fibres observed following treatment with codon-
optimised ∆R4-R23/∆CT is vastly superior to treatment with codon-optimised ∆AB/R3-
R18/∆CT, with no evidence of cytoplasmic staining, making these treated muscles
difficult to distinguish from wild type muscles (Figure 4a-h). In accordance with these 
observations, central nucleation, a marker of myofibre regeneration, is normalised in 
muscles treated with codon-optimised ∆R4-R23/∆CT, but is not improved compared to 
mdx following treatment with AB/R3-R18/CT (Figure 5a). Young adult mdx mice 
exhibit increased muscle mass compared to age matched controls; treatment with
control rAAV2/8 ∆AB/R3-R18/∆CT has no effect on mass, whilst treatment with codon-
optimised ∆AB/R3-R18/∆CT reduces TA mass significantly (p<0.05), but is still greater 
than wild type controls. However, administration of rAAV2/8 ∆R4-R23/∆CT reduces the 
6mass of the mdx TA to such an extent that there is no significant difference to wild type 
muscle (p=0.8; Figure 5b).
Delivery of rAAV2/8 codon-optimised microdystrophin leads to greater
improvements in mdx muscle function. 
Morphological changes in skeletal muscle of the mdx mouse are due to the lack of 
dystrophin and the deleterious effect that this has on muscle function. To test the ability 
of microdystrophin constructs to improve muscle function, we administered 7.5x109
vector genomes of a rAAV2/8 expressing either ∆AB/R3-R18/∆CT or codon-optimised
∆AB/R3-R18/∆CT or ∆R4-R23/∆CT under the control of the muscle specific promoter 
Spc5-12, into the TA muscle of 5 day old mdx mice. Mdx mice typically exhibit an 
increased maximal tetanic force, but a reduced specific force (force normalised for cross
sectional area of the muscle) compared to age matched controls. Injection of rAAV2/8 
∆AB/R3-R18/∆CT had no effect on either maximal tetanic or specific force compared to 
untreated mdx. However, specific force was significantly improved following treatment 
with codon-optimised rAAV2/8 ∆AB/R3-R18/∆CT (p<0.01), but was still reduced 
compared to wild type mice. In comparison, treatment with codon-optimised rAAV2/8 
∆R4-R23/∆CT normalised maximal tetanic force, such that specific force was improved
significantly compared to mdx mice (p<0.001), and showed no difference to the specific 
force generated by wild type mice (Figure 6a-c). 
In addition, we tested the ability of codon-optimised microdystrophins to protect mdx 
myofibres from exercise induced damage, by assessing maintenance of force 
7production following a series of eccentric contractions. Treatment with either rAAV2/8 
∆AB/R3-R18/∆CT or the codon-optimised construct was unable to protect mdx muscle 
from force deficit induced by eccentric contractions (Figure 7). However, treatment with 
codon-optimised rAAV2/8 ∆R4-R23/∆CT provided substantial protection from force 
deficit over a series of 10 eccentric contractions (compared to untreated mdx p<0.001). 
In addition, the force deficit curve produced by muscles treated with codon-optimised
∆R4-R23/∆CT does not show a significant difference compared to the curve produced 
by wild type muscles (p=0.31; Figure 7). 
8Discussion:
This study has focused on the application of codon optimisation of a eukaryotic gene 
under the control of a muscle restrictive promoter to enhance gene expression and 
therefore functionality following plasmid and rAAV gene transfer. Both plasmid and rAAV 
gene transfer are being intensively investigated as potential therapeutic avenues for the 
treatment of DMD. Key to both these strategies is the ability to deliver the transgene 
efficiently to skeletal and cardiac muscle to produce robust levels of dystrophin 
expression under the control of a muscle restrictive promoter. In the case of rAAV, this 
must be achieved at viral doses that are not prohibitive. Here, we have optimised the 
codon usage of two different microdystrophin cDNA sequences and compared their 
expression and functionality to each other, and to a non-codon-optimised control.
Microdystrophin cDNA sequences were optimised in a number of ways to improve 
mRNA stability and translation efficiency. Sequences flanking the AUG start codon 
within an mRNA can influence its recognition by eukaryotic ribosomes. A consensus 
Kozak sequence has been shown to be important and required for the optimal 
translation of mammalian genes (13, 14). A second point at which efficiency of 
translation can be improved is by optimisation of codon usage. Codon bias is observed 
in many species with the greatest deviation from random codon usage seen in highly 
expressed genes. Optimisation of codon usage for the species in which the transgene is 
expressed has resulted in significantly higher levels of protein expression, particularly 
when expressing viral proteins for genetic vaccination purposes (13, 15, 16). 
Microdystrophin cDNAs used in this study were modified to include a consensus Kozak 
9sequence, codon usage was modified based on tRNA frequencies in human, and GC 
content was increased to promote mRNA stability (17). We have demonstrated that by 
optimising the cDNA sequence of a eukaryotic gene for expression in a eukaryotic 
system, levels of mRNA can be significantly increased, as can the number of dystrophin 
positive fibres following intramuscular plasmid gene transfer and systemic rAAV gene 
transfer. This observation is in accordance with recent data which demonstrate
optimised protein expression of eukaryotic genes through either incorporation of a 
Kozak sequence (18) or codon optimisation (19).
Although mRNA levels from both codon-optimised constructs are equivalent, levels of 
protein expression seen following both plasmid and rAAV gene transfer was much 
higher with microdystrophin ∆R4-R23/∆CT than ∆AB/R3-R18/∆CT (through increased 
numbers of fibres and over expression within individual fibres). Transfection of skeletal 
muscle fibres with each of the microdystrophin constructs whether by viral or non-viral 
vectors should be equally efficient, and as mRNA production from both plasmids also 
appears to be equal, the difference in levels of protein expression may be attributed to 
protein stability. This is manifest at 1 week post electrotransfer as accumulation of 
microdystrophin R4-R23/CT within the cytoplasm of transfected fibres, although at 
this time point equal numbers of positive fibres were observed. By 8 weeks post rAAV 
gene transfer higher numbers of microdystrophin positive fibres are observed in the 
R4-R23/CT treated group compared to codon-optimised ∆AB/R3-R18/∆CT. This
difference may be due to the loss of ∆AB/R3-R18/∆CT fibres over time as a result of 
lower bio-functionality of the protein or protein instability.   
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rAAV is a non-pathogenic, replication defective parvovirus, which is being extensively 
investigated as a gene delivery vehicle due to its apparent ability to exhibit prolonged 
transgene expression in the absence of an immune response. Many different serotypes 
of AAV have been described (20-22). Of relevance to DMD are those which show very 
high tropism for skeletal and cardiac muscles and in particular are able to transduce 
these tissues following systemic administration. A number of groups have demonstrated 
this effect with rAAV serotypes 6, 8 and 9 (7, 12, 23, 24). Although very dramatic levels 
of gene transfer were achieved in these studies, high titres of rAAV were required to 
achieve these levels of transduction (7). Scaling up these doses to larger animal models 
and humans involves technical issues; in terms of manufacturing large enough batches 
of virus and avoiding immune complications associated with delivery of such large viral 
doses. Optimisation of cDNA sequences for gene therapy may be one way to reduce the 
viral dose required for efficient gene transfer. 
rAAV vector serotypes 8 and 9 are of particular interest for gene therapy of DMD due to 
their ability to transduce both cardiac and skeletal muscle. Although skeletal muscle is 
initially the primary clinical feature of DMD, cardiac and respiratory failure are the main 
causes of morbidity in these patients. Recent data from transgenic mdx mice that 
express dystrophin in skeletal muscle but not cardiac muscle demonstrated a five fold 
increase in cardiac injury (25), most likely due to increased activity in these mice, 
underlying the importance of treating both cardiac and skeletal muscle in DMD patients.
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Optimisation of microdystrophin ∆R4-R23/∆CT cDNA resulted in high levels of 
expression of microdystrophin in both cardiac and some skeletal muscles following 
systemic administration of 3x1011vg rAAV2/8. Comparable studies where 3x1011vg of 
rAAV2/8 CMV LacZ vectors have been administered via the same route, have similarly
achieved good levels of expression in the heart, but very low levels of transduced fibres
in skeletal muscle (12, 23). In contrast to these studies, we demonstrate that we can 
achieve significant levels of microdystrophin expression in cardiac and skeletal muscles 
under the control of the muscle restrictive promoter Spc5-12 following an equivalent 
dose of rAAV2/8. It should be noted that this dose of rAAV2/8 did not achieve the body 
wide skeletal muscle gene expression previously demonstrated with much higher doses 
(7.2x1012vg) of rAAV8 (12), but is encouraging that cardiac and skeletal muscle 
systemic gene transfer may be achieved with much lower doses than has previously 
been required, particularly in conjunction with serotypes such as rAAV9 which exhibit 
higher tropism for muscle cells (23, 26).
The second aim of the study was to compare the functional properties of the optimised 
microdystrophin cDNA’s. Expression of non-optimised AB/R3-R18/∆CT in neonatal mdx 
muscle (following i.m. injection) had no impact on the progression of the dystrophic 
pathology, however optimised microdystrophin AB/R3-R18/∆CT improved specific force 
compared to untreated mdx muscle. This improvement is likely to be due to the increase 
in number of dystrophin positive fibres, but this did not result in any improvement in 
muscle pathology markers such as central nucleation. In comparison, expression of 
microdystrophin ∆R4-R23/∆CT was able to completely prevent the onset of dystrophic 
pathology in mdx mice by all parameters tested. The configuration of microdystrophin 
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∆R4-R23/∆CT is based upon a microdystrophin described by the Chamberlain group (8).
This construct has previously been shown to be highly functional, demonstrating 
improvements in both muscle function and muscle pathology, following gene transfer to 
neonatal, young and old mdx mice (6, 7, 11, 27). In comparable studies where mdx mice 
have been treated with rAAV as neonates (10, 27), specific force and levels of central 
nucleation have been improved, with minimal improvements observed in resistance to 
eccentric contractions. Despite 10 fold fewer viral genomes being administered in the 
current study, we demonstrate complete normalisation of specific force and levels of 
central nucleation. We also demonstrate a substantial improvement in protection from 
eccentric contractions, using a protocol more physiologically relevant to the protocol 
employed by Banks et at (10). As the rAAV microdystrophin vectors used by the 
Chamberlain group have essentially the same configuration including an optimal Kozak 
sequence (8), the improved outcome that we observe may be a reflection of the 
increased levels of dystrophin fibres and protein, as a result of codon optimisation and 
the use of highly efficient serotype rAAV2/8 vectors.
For the first time this study directly compares the functionality of two previously 
described microdystrophin configurations (4, 8). Whilst codon optimisation improved the 
functional outcome following treatment with rAAV2/8 AB/R3-R18/∆CT, it is clear that 
microdystrophin ∆R4-R23/∆CT is more functionally protective against the pathological 
changes that occur in mdx muscle. One possible explanation for this difference is the 
higher number of dystrophin positive fibres observed in these mice, as recovery of
muscle function in mdx mice may be related to the number of dystrophin positive fibres 
and the levels of dystrophin expression within the muscle.
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The reduced function of microdystrophin AB/R3-R18/∆CT may also be attributed to 
deletions within the actin binding domain 1 (ABD1) at the N-terminus of the protein, 
which microdystrophin ∆R4-R23/∆CT does not have. Full length dystrophin has two ABD 
domains, ABD1 at the N-terminus of the protein and ABD2 within the rod domain. 
Studies in transgenic mice have demonstrated that the lack of both ABDs leads to a 
severe dystrophic phenotype (28), whilst deletion of a single ABD, including the deletion 
included in microdystrophin AB/R3-R18/∆CT can lead to a relatively mild phenotype (1, 
29-31). We have shown previously that this microdystrophin can lead to histological 
improvements in the dystrophic phenotype of mdx mice (4), but the combination of 
deletions in ABD1 and of the entire ABD2 may provide insufficient actin binding to 
achieve functional stability at the levels observed with microdystrophin ∆R4-R23/∆CT. 
This is supported by the recent study of Banks et al which studied the effects of 
deletions in ABD1 of a microdystrophin with the same configuration as ∆R4-R23/∆CT
(10), although, in contrast to our study, there was no observed improvement in either 
specific force or resistance to eccentric contractions. 
The lower functional capacity of microdystrophin AB/R3-R18/∆CT may also explain 
why we observe much lower numbers of dystrophin positive fibres at 8 weeks post 
injection compared to microdystrophin ∆R4-R23/∆CT. Quantitative RT-PCR analysis 
showed that mRNA levels were increased equally by codon optimisation of these 
constructs; we would have expected to see equal levels of dystrophin expression but at 
8 weeks post injection this was not the case. It is possible that the number of dystrophin 
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positive fibres were initially equivalent (as observed following plasmid gene transfer), but 
declined in rAAV2/8 AB/R3-R18/∆CT treated mice due to incomplete protection against 
necrosis and degeneration of dystrophin positive fibres. A similar effect was observed by 
Banks et al following neonatal administration of microdystrophins containing ABD1 
deletions (10). 
We conclude that optimisation of microdystrophin cDNA sequences for codon usage, 
GC content and the inclusion of optimal Kozak sequences, can significantly improve the 
outcome of gene transfer studies through maximising gene expression and protein 
levels. This system will be applicable to both viral gene transfer in allowing effective viral 
doses to be reduced and increasing the efficiency of vector production (19), and also in 
improving efficiency of non viral gene transfer not only to muscle but across the whole 
field of gene therapy.  
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Materials and Methods:
Generation of constructs
Non codon-optimised human microdystrophin ∆AB/R3-R18/∆CT was constructed as 
previously described (4). Codon-optimised cDNA sequences of human and murine 
microdystrophins ∆AB/R3-R18/∆CT and ∆R4-R23/∆CT were generated by Geneart
(Regensburg, Germany). These cDNA sequences, including an optimal Kozak 
sequence, were cloned into a pDD derived AAV plasmid (32) under the control of the 
muscle restrictive promoter Spc5-12 (33). HEK293T cells were transfected with the 
expression plasmid and the helper plasmids pAdF6 and pAAV5E18-VD2/8 (J. Wilson, 
University of Pennsylvania, USA) by means of calcium phosphate precipitation (34). Cell 
pellets were harvested and lysed in 50mM Tris-Cl, 150mM NaCl. Lysates were clarified 
by centrifugation at 6700rpm for 20 mins and passed through a 0.45m filter. Cell 
lysates were layered on an iodixanol gradient (Sigma-Aldrich, Poole, UK,) and 
centrifuged at 60,000rpm for 90 mins.  The 40% iodixanol layer containing the viral 
particles was isolated, concentrated with PBS, 5mM MgCl2, 12.5mM KCl (PBS-MK), 
through a Amicon Ultra 15 100KDa (Millipore UK).  The number of vector genomes was
determined relative to a plasmid DNA standard using Dot blot hybridization.     
Tissue culture and qRT-PCR
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HEK293T cells were grown and maintained in DMEM, 10%FCS at 8% CO2 in a 
humidified incubator.  Cells were seeded at a density of 1x104 cells/cm2 in a 6 well plate 
and transfected with 4g plasmid DNA (p∆AB/R3-R18/∆CT, codon-optimised p∆AB/R3-
R18/∆CT or p∆R4-R23/∆CT) using Lipofectamine 2000 (Invitrogen, Paisley, UK). All 
transfections were carried out in quadruplicate. Cells were harvested after 48 hours and 
RNA was extracted using an RNeasy Kit (Qiagen, Crawley, UK).
Total RNA (1μg) was reverse transcribed in a final volume of 25μl containing 5μl  5x RT 
buffer, 25U RNasin RNase inhibitor, 5μl 10mM dNTP, 200U M-MLV Reverse 
Transcriptase (Promega, Southampton, UK) and 2.5μM random nonamers (Sigma). 
Reactions were incubated at 42C for 60 min and reverse transcriptase was inactivated 
by heating at 70C for 15 min and cooling at 4C for 5 min. 
Specific primer sets were as follows (5’3’): for microdystrophin, 
AACAAAGTGCCCTACTA (forward) and AGGTTGTGCTGGTCCA (reverse); for 
ribosomal RNA 18S TTGACGGAAGGGCACCACCAG (forward) and 
GCACCACCACCCACGGAATCG (reverse). For each experiment a reaction mix was 
prepared; for each tube 2.5μl forward primer (20nM), 2.5μl reverse primer (20nM), 2.5μl 
RNAse-free DNAse-free water and 12.5μl SYBR Green Master Mix (Eurogentec 
Southampton, UK). Aliquots (20μl) of this mix were placed in the SmartCycler tubes and 
5μl cDNA solution was added to each reaction. All reactions were processed in 
duplicate. The experimental run protocol was: denaturation (95C for 10 min) and 40 
cycles of 95C for 15s, 60C for 30s, 72C for 30s with a single fluorescence 
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measurement. Melting curve program (60-95C with heating at 0.1C per second and 
continuous fluorescence measurement). mRNA concentrations were normalised to that 
of the ribosomal 18S RNA in each sample.
Administration of rAAV
Wild type C57Bl/10 and mdx mice were housed in minimal disease facilities (Royal 
Holloway, University of London and Imperial College London) with food and water ad 
libitum. For physiological studies 5 day old neonatal mdx mice were anaesthetised by 
indirect contact with ice and injected intra-muscularly with 7.5x109 vector genomes (vg)
of rAAV expressing human microdystrophins in 5l PBS-MK. Physiological and 
histological assessment was performed at 8 weeks post administration of rAAV.
Systemic administration of rAAV was performed in 10 week old mdx mice. Mice were 
restrained and 3x1011 vg in 100l of PBS-MK of rAAV expressing microdystrophins were 
injected via the tail vein. Histological analysis was performed at 12 weeks post 
administration of rAAV.      
Electrotransfer of plasmid DNA
Two hours prior to the injection of plasmid DNA, 25l of bovine hyaluronidase (Sigma)
solution (10U) was injected intra-muscularly into the TA muscle of 6-8 week old mdx 
mice, under fentanyl/fluanisone (VetaPharma Ltd, Leeds, UK) and midazolam (Roche, 
Lewes, UK) general anaesthesia. Immediately after the injection of 25g plasmid DNA
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into the TA, electrotransfer was carried out as follows: Using a BTX 830 electroporator 
with Tweezertrodes (Genetronics, San Diego, USA) electric pulses were applied to the 
mouse hind limb. Electrodes were placed in medial and lateral positions relative to the 
TA. For each treatment, a voltage of 175V/cm was applied in ten pulses of 20ms each, 
at a frequency of 1Hz. Each TA muscle was measured prior to electrotransfer so that 
voltage could be adjusted accordingly. Electrotransfer was performed under isoflurane 
gaseous anaesthetic. 
Histology
Recovered tissues were mounted in Cryo-M-Bed (Bright Instruments, Huntingdon, UK) 
and snap frozen in liquid nitrogen cooled isopentane. Dystrophin staining was carried 
out on 10m cryosections. Frozen tissue sections from control and treated mice were air 
dried for 30mins and blocked using an avidin/biotin blocking kit and Mouse on Mouse kit
(Vector Ltd, Peterborough, UK). Microdystrophin was detected with a primary antibody 
(at a dilution 1/50) against repeat region 1 of the rod domain (MANEX 1011C, Glenn
Morris, Oswestry, UK). Sections were incubated with primary antibody for 30 minutes 
and then washed in PBS. Immunostaining was completed using secondary antibody and 
avidin/biotin amplification system from Mouse on Mouse kit. Dystrophin staining was 
visualised using 3,3'-diaminobenzidine (Vector Ltd.).
To assess central nucleation and pathology muscles were stained with haematoxylin
and eosin. Cryosections were air dried for 30 minutes and stained with Mayer’s
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haematoxylin (Sigma) for 1 minute and washed in tap water for 3 minutes. Sections 
were counterstained with 1% eosin (VWR, Lutterworth, UK) for 5 minutes. Sections were 
dehydrated in 100% ethanol, cleared in xylene and mounted in DPX (VWR). To assess 
central nucleation three random areas were assessed in each treated and control (mdx 
and wild type) mouse (n=6 per group). The total number of fibres in these areas was
counted and the number of centrally nucleated fibres was expressed as a percentage of 
the total number of fibres. To assess numbers of dystrophin positive fibres, the number 
of positive fibres was counted in four random fields of a muscle section and the average 
number per field was calculated for each muscle. 
  
In situ muscle function and lengthening contraction protocol
Mice were anaesthetised with an intra-peritoneal injection of fentanyl/fluanisone, 
midazolam and water (1:1:2 by vol.) at a dosage of 10ml/kg. The mice were carefully 
monitored throughout the experiment and additional doses of anaesthetic were 
administered to ensure that there was no reflex response to toe pinch. Under deep 
anaesthesia the distal tendon of the tibialis anterior (TA) muscle was dissected from 
surrounding tissue and the tendon tied with 4.0 braided surgical silk. The sciatic nerve 
was exposed and all its branches cut except for the common peroneal nerve (CPN), 
which innervates the TA muscle. The mouse was placed on a thermopad (Harvard 
Apparatus) to maintain body temperature at 37ºC. The foot was secured to a platform 
and the ankle and knee immobilized using stainless steel pins. The TA tendon was 
attached to the lever arm of a 305B dual-mode servomotor transducer (Aurora Scientific 
Inc., Ontario, Canada) via a custom made steel s-hook.  
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TA muscle contractions were elicited by stimulating the distal part of CPN via bipolar 
platinum electrodes, using supramaximal square-wave pulses of 0.02 ms (701A 
stimulator; Aurora Scientific Inc). Data acquisition and control of the servomotors were 
conducted using a Lab-View based DMC program (Dynamic muscle control and Data 
Acquisition; Aurora Scientific, Inc.). Optimal muscle length (Lo) was determined by 
incrementally stretching the muscle using micromanipulators until the maximum 
isometric twitch force was achieved. Maximum isometric tetanic force (Po) was 
determined from the plateau of the force-frequency relationship following a series of 
stimulations at 10, 30, 40, 50, 80, 100, 120, 150, and 180 Hz. A one minute rest period 
was allowed between each tetanic contraction. Muscle length was measured using 
digital calipers based on well defined anatomical landmarks near the knee and the 
ankle. The specific force (N/cm2) was calculated by dividing Po by TA muscle cross-
sectional area (CSA). Overall CSA was estimated using the following formula: muscle 
weight (g) / [Lo (cm) x 1.06 (g/cm
3). 
After establishing the force-frequency relationship, the susceptibility of TA muscles to 
eccentric contraction-induced injury was assessed. This consisted of stimulating the 
muscle at 180 Hz (the frequency that usually resulted in Po) for 700 ms. After 500 ms of 
stimulation the muscle was lengthened by 10% of Lo at a velocity of 0.5 Lo s/1. At the 
end of stimulation the muscle was returned to Lo at a rate of -0.5 Lo s/1. The stimulation-
stretch cycle was repeated every 3 min for a total of 10 cycles. The rest time between 
each cycle limited the potential for developing muscle fatigue. Maximum isometric force 
was measured after each eccentric contraction and expressed as a percentage of the 
21
initial maximum isometric force. At the end of the experiment the muscles were excised, 
weighed and prepared for histological analysis. 
Statistical Analysis
All data are presented as mean values SEM (cohort size stated per experiment). All 
statistical analysis was performed by one way ANOVA followed by Tukey-Kramer post-
hoc analysis. 
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Figure Legends:
Figure 1 Codon optimisation of microdystrophin increases mRNA and protein 
levels following plasmid gene transfer.
(a) Quantitative RT-PCR of microdystrophin mRNA 48 hours post transfection of 
HEK293T cells. Levels of microdystrophin mRNA are expressed relative to the 
housekeeping gene Ribosome18S. (b) Total number of microdystrophin positive fibres 
at 7 days post electrotransfer of 25g plasmid DNA in TA of mdx mice (6-8 week old). 
(c&d) Dystrophin staining using MANEX1011C in treated TA muscles (c) codon-
optimised AB/R3-R18/CT (d) codon-optimised AB/R3-R18/CT.  Error bars are 
mean ± s.e.m (n=4, * p<0.05 compared to non codon-optimised AB/R3-R18/CT). 
Scale bar = 300m. 
Figure 2 Efficient cardiac gene transfer following systemic administration of 
codon-optimised microdystrophin.
Average number of microdystrophin positive cardiomyocytes within a field of 
myocardium following administration of 3x1011vg AAV8 microdystrophin via the tail vein 
of 10 week old mdx mice. Analysis was performed 12 weeks post- injection. Error bars 
shown as mean ±s.e.m (n=4). *p<0.001 compared to non-codon-optimised AB/R3-
R18/CT, **p<0.001 compared to non-codon-optimised AB/R3-R18/CT and codon-
optimised AB/R3-R18/CT.   
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Figure 3 Expression of codon-optimised R4-R23/CT microdystrophin following 
systemic administration rAAV2/8 vectors.
Tissue sections were stained for codon-optimised R4-R23/CT microdystrophin 
expression using monoclonal antibody MANEX1011C (1/50). Scale bar = 300m
Figure 4 Codon-optimisation of microdystrophin leads to increased numbers of 
dystrophin positive fibres following intramuscular injection of rAAV2/8 vectors.
TA muscles of neonatal (5 day old) mdx mice were injected with 7.5x109vg rAAV2/8 
microdystrophin and analysed histologically at 8 weeks post injection. Sections were 
either stained for microdystrophin using the anti-dystrophin antibody MANEX1011C 
(1/50), or with haematoxylin and eosin. Scale bar = 300m
Figure 5 Intramuscular delivery of codon-optimised microdystrophin improves 
morphological properties of mdx muscle.
TA muscles of neonatal (5 day old) mdx mice injected with 7.5x109vg AAV2/8 
microdystrophin were (a) assessed histologically at 8 weeks post treatment to determine 
the percentage of centrally nucleated fibres within the TA muscle (b) and weighed. Error 
bars shown as mean ±s.e.m. (n=6) *p<0.05 compared to mdx, **p<0.001 compared to 
mdx and no significant difference compared to C57bl/10. 
Figure 6 Intramuscular administration of codon-optimised microdystrophin leads 
to greater improvements in functional properties of mdx muscle.
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TA muscles of neonatal (5 day old) mdx mice injected with 7.5x109vg AAV2/8 
microdystrophin were analysed at 8 weeks post injection for their maximal force 
producing capacity compared to untreated mdx muscle and C57bl/10 age matched 
controls. Maximal force was also normalised for cross sectional area of the muscle to 
assess specific force. (a) AB/R3-R21/CT, (b) codon-optimised AB/R3-R21/CT, (c) 
codon-optimised R4-R23/CT. Error bars shown as mean +/- s.e.m (n=6). *p<0.05 
compared to mdx and C57bl/10, **p<0.001 compared to mdx control and no significant 
difference to C57bl/10.   
Figure 7 Intramuscular administration of codon-optimised R4-R23/CT leads to
protection from lengthening contractions.
TA muscles of neonatal (5 day old) mdx mice injected with 7.5x109vg AAV2/8 
microdystrophin were analysed at 8 weeks post injection. Treated and control muscles 
were assessed for force deficit following a series of ten lengthening contractions. 
Maximal tetanic force following each lengthening contraction is displayed as a 
percentage of initial maximal tetanic force. (a) AB/R3-R21/CT, (b) codon-optimised 
AB/R3-R21/CT, (c) codon-optimised R4-R23/CT. Error bars shown as mean +/-
s.e.m (n=6). **p<0.001 compared to mdx control and no significant difference to 
C57bl/10. 
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